Overview

BioMedical Technology Solutions Inc., a wholly owned subsidiary of BioMedical Technology Solutions Holdings, Inc., provides innovative solutions for environmentally friendly disposal of biomedical waste. Located in Englewood, Colorado, the Company sells and leases the patented Demolizer® II System, the GREEN alternative to biomedical waste disposal. BMTS offers safer, more environmentally sound, biomedical waste treatment solutions for medical, dental and veterinary offices, nursing homes, assisted living facilities, and other health care facilities.

---

Investment Highlights

---

Profile

Biomedical Technology Solutions Holdings, Inc. (“BMTS” or the “Company”) develops, manufactures and markets proprietary, branded biomedical waste disposal systems for use in virtually all low to mid volume point of care settings including physician, dental and veterinary clinics, with other public settings including airports, hotels and large entertainment arenas.

Current methods of biomedical waste disposal involve safety risks, costly transportation and treatment, and carry the probability of untreated waste spillage, improper treatment or unlawful dumping which are harmful to the environment.

BMTS's point of care disposal systems eliminate the need for popular transportation based services, including the inherent risks and costs. BMTS‟ dry heat systems offer a superior alternative to conventional transportation programs by eliminating the costs, risks and environmental dangers associated with storage, transportation and offsite treatment, while eradicating the possibility of inadvertent public health hazards associated with the improper handling and treatment of waste.

BMTS's patented Demolizer® technology systems employ a repeat business model with the Demolizer®II dry heat waste disposal unit (the razor) and the collector (the razor blade) providing the user a long-life, cost effective and simple to use method to safely dispose of typical sharps and red bag waste at the point of care.

The original patented Demolizer® biomedical waste processing system was developed in 1993 by Thermal Waste Technologies, Inc. (TWT) and has successfully completed over 300,000 processes. In 2005, the Demolizer® patented technology was acquired by BioMedical Technology Solutions, Inc., and the Demolizer® system was enhanced with advanced quality control, hardware and remote diagnostics. BMTS introduced the Demolizer® II in late 2006, a reconfigured, improved version, which uses the patented Demolizer® technology.

The Demolizer® II is a unique, cost-effective system for low to medium volume medical waste generators, is approved, or meets regulatory requirements in 47 states, for treatment and disposal of both sharps and red bag waste. About the size of a desktop printer, the Demolizer® II ensures complete disposal of medical waste, automatically documents state-required records, and eliminates the generator's cradle-to-grave liability. The patented treatment process, using dry heat technology, renders waste sterile and sharps unrecognizable. The treated waste is properly labeled and simply thrown away as common trash.

Savings, Safety, Simplicity and Security are the four main ways customers benefit from using the Demolizer® II system.

The system saves customers thousands by eliminating or dramatically reducing biomedical waste hauling costs and often pays for itself in one year or less.

Customers enjoy safer facilities because potentially hazardous biomedical waste is no longer handled multiple times or stored onsite, awaiting hauler pickup.

The process is simple to start and complete and needs no special chemical or electrical requirements. On completion, treated waste is thrown in common trash, and all state-required documentation is automatically generated.

The Demolizer® II is a proven, tested and approved solution to securely eliminate biomedical waste generator's cradle-to-grave liability without harming the environment.

The Company's technology is protected by their existing patent and patents pending worldwide on the system and the collectors. The Company is constantly researching and developing improvements to their technology and continue to protect their intellectual property enhancements with additional filings.

There are more than one million low to medium volume generators of medical waste in the United States, and millions more worldwide. The Demolizer® II system is well-positioned to capture significant biomedical waste management market share in nursing homes, clinics, veterinary, public venues and military health care facilities.

The Company's product is gaining in popularity among their target markets, which is quite evident in their Q1 2009 numbers. The Company's first quarter net revenue increased 157% to $359,305 versus net revenue of $139,654 in the first quarter last year. The increase reflects the success of the Company's new sales and marketing division, HealthCare Sales Professionals, Inc. that was launched in January 2009. Q2 of 2009 revenues also came in at $365,211 in 2009 as the Company continued to make strides with their distribution networks and sales volumes.

Revenues could increase given the Company's announcement in May 2009 of the signing of a multinational distribution partnership with Novismed Corporation (Miami, Florida) for the broadscale sale and distribution of the Demolizer II System in Central and Latin America and the Caribbean. Novismed has established long-term seasoned partnerships with key distributors in Central America, Latin America and the Caribbean with expansive coverage in over 15 countries including very large markets such as Mexico, Chile, the Caribbean and Argentina. Many of these countries currently rely heavily on incineration or landfilling of untreated medical waste and are looking for safer and more environmentally responsible alternatives. Novismed Corporation, with its proven leadership and extensive networks, has the capabilities to introduce the Demolizer II technology to Central and Latin America and the Caribbean healthcare markets on a broad scale.

Lastly, in April of 2009, Frost & Sullivan recognized BioMedical Technology Solutions (BMTS), Inc. with the prestigious 2009 North American Frost & Sullivan Award for Product Innovation of the Year. The company has outpaced its competitors in product innovation, as evidenced by its introduction of the Demolizer(R) II. Receiving recognition from a worldwide consulting corporation such as Frost & Sullivan is an award that should not be taken lightly. Frost & Sullivan, founded in 1961, has more than 35 global offices with more than 1800 industry consultants, market research analysts, technology analysts and economists. In 2005 and again in 2006, Frost & Sullivan was ranked #1 in the industry in terms of revenue growth, thus providing great credibility that Frost & Sullivan has what it takes to be a growth consultant for its clients. Frost & Sullivan has consistently out performed the average industry growth rates of the market research, corporate training, information and consulting industry.

When looking at the technical chart as well as the trading history for BMTL, two things strike out. First off, the Company is trading near its 52 week low after experiencing a downtrend that began in July of this year.  While that does sound like bad news, it is encouraging for us because most of the technical indicators are pointing to BMTL as being significantly oversold, and given it's proximity to its 52 week low, it could be primed for a significant bounce back. There is not much reasoning behind the significant drop in the stock price since July and as such, given the news that was announced tonight after the bell, it may prove to be the catalyst for a change in trend direction. We encourage investors to closely watch trading in BMTL tomorrow as investors digest tonight's news and re-assess the Company's fundamentals.

---

Future Growth Catalysts

Developing countries have serious barriers to effective biomedical waste disposal. BMTS is working with global health leaders to combat those barriers by designing a system specifically for use in these developing areas.

The home health care (self-injector) market, although not rigorously regulated currently, is the source of billions of injections in the United States alone. Increasing pressure for regulatory oversight of the home health market will set the stage for market entry of the home Demolizer® unit currently in the initial design phase.

BMTS is also actively engaged in finding environmentally friendlier ways to process biomedical waste. The Company is currently researching and working to develop recycling programs for their technology, including a 100% recyclable filter and an effectively and thoroughly recycled Demolizer® technology processed end-product.

---

Industry Perspective

• Over 1.5 billion pounds of biomedical waste are generated in the U.S. per year, equaling more than 5 lbs per person.
• Cost for management of this waste in the U.S. is estimated at $3.5 billion.
• The global commercial medical waste market is estimated at 5 times the U.S. market (> 7 billion pounds) with an approximate market value of $6.5 billion.
• In 2006, an estimated 8 million people in the U.S. administered 3 billion injections at home annually. This figure is expected to grow 165% over the next ten years.
• By 2016, 21 million people in the U.S. will administer 8 billion injections.
• Majority of self-injections are diabetes related with a new person in the U.S. diagnosed with Type II diabetes every 21 seconds.
• California and Massachusetts have enacted new laws prohibiting landfill disposal of home-generated sharps. Many other states are starting to focus on this emerging public health problem.
• There are approximately 20,000 trucks in service each day hauling nothing but biomedical waste from the point of care to its ultimate treatment or landfill destination, consuming valuable fuel and expelling harmful emissions, requiring significant infrastructure investment for this specific purpose and wasting countless other valuable resources.

Demolizer Home Unit

• Designed to solve the home-generated sharps waste problem.
• Consumer appliance designed to the same rigorous standards for domestic and international use.
• The Home unit will be the size of a common toaster and boast recyclable collectors with a "razor" / "razor blade" business model.
• Anticipated launch in early 2010.

---

Technology

• The Demolizer technology was invented in 1993, patented in 1999, and has over 350,000 processes to-date.
• The Demolizer® II has demonstrated high level disinfection (>6 log10 reduction; 99.9999% efficiency) of important indicator organisms including the USP indicator resistant spore organism B. atrophaeus, MSRA, E. coli, M. phleiand C. albicansin studies conducted at Kansas State University.
• The Demolizer technology meets EPA and CDC standards, and is either formally approved or meets the requirements for biomedical waste treatment and disposal in 47 US states having successfully passed 78 independent governmental agencies‟ evaluations.
• The Company and its products have an exemplary track record free of legal or compliance issues.
• BMTS was awarded Frost and Sullivan's prestigious 2009 North American Medical Waste Treatment Product Innovation of the Year Award.
• The Demolizer® technology has been exhaustively tested at Kansas State University, Stanford University and private laboratories in support of state regulatory approvals.
• The system automatically generates labels for immediate documentation, then stores process data, making state required documentation effortless and the generator's cradle-to-grave liability virtually eliminated.

---

BMTS Difference

Conventional Disposal Methods
Collection: FDA approved sharps collector is standard for all	Storage: Requires ample square footage for safe storage between pick-ups OSHA compliance issues with seals State compliance with storage time limitations	Transportation: High cost service Infrastructure investment for hauler Significant fuel, labor & other operating costs Real possibility of spillage, mishandling or improper treatment	Off Site Treatment: Environmental issues Significant infrastructure investment Ongoing burn rate Unintended consequences
BMTS Demolizer Method – Environmental Responsibility
Collection: FDA approved sharps collector is standard for all	Treatment: Simple, timely process No airborne pathogens No by-products Compliance record keeping & backup	Disposal: Common trash

---

Recent News and Press Releases

BMTS Announces Pilot In-Store Demolizer(R) II Sharps Disposal Program
Marketwire (Tue, Oct 6)

 

BioMedical Technology Solutions Holdings, Inc. Earnings Call scheduled for 8:30 am ET today
CCBN (Wed, Aug 19)

BMTS Announces Q2 2009 Financial Results and Conference Call
Business Wire (Wed, Aug 12)

BMTS Signs National Distribution Agreement With Physicians Alliance of America
Marketwire (Thu, Jun 11)

BioMedical Technology Solutions Holdings, Inc. First Quarter Net Revenue Increases 157%
Marketwire (Tue, May 19)

BMTS Signs Multinational Agreement With Novismed Corporation for the Distribution of the Demolizer(R) II System in Central and Latin America and the Caribbean
Marketwire (Thu, May 14)
 

---

Management

Don G. Cox, Jr. serves as President, Chief Executive Officer, and Chairman of the Board of the Company. Don Cox is considered a leading expert in the retail industry for his proven ability to take a product from an idea to a concept and successful deployment both domestically and internationally. He has over twenty-five years experience in raising capital, contract negotiations, licensing, product design, operations, sales, and marketing. He has consulted for several companies in the areas of mergers, acquisitions, and exit strategies. He has a unique ability to build management teams with extensive expertise and very diverse backgrounds to create successful companies that are on the leading edge of their industries.

Mr. Cox was once the largest national franchise operator of TCBY stores in the 1980s, chairing TCBY’s President’s Council, and an owner of a large area development agreement with Blockbuster. Most notably, he served as President, CEO and Chairman of the Board of Directors of Pretzelmaker, Inc. He took Pretzelmaker, a company on the verge of bankruptcy, to 220 stores in 40 states and 7 provinces in Canada and Asia in 18 short months. It became one of the fastest growing franchise chains in North America, outgrowing competitors nearly three to one and becoming one of Entrepreneurs Magazine’s top 200 franchises in 1996. As President and CEO, he was responsible for product development and store design, marketing and distribution, both domestic and international, and franchise business operations.

Mr. Cox was co-founder, President and Chief Executive Officer of Body, Art and Science and SRA (Supplement Research and Advancements), a high-end sport supplement and nutrition company with products distributed in the U.S. and Europe. He is considered an expert in both the fitness and nutritional industries consulting for athletes in the NFL and NBA. Mr. Cox also developed and owned Fitness Unlimited and Florida Fitness, two successful fitness chains in Florida. He is the founder of Namaste®, an all natural, all botanical skin care line developed for women, men and children with over 90 products. Namaste® was sold in major department stores including Nordstrom and Takashmia on 5th Avenue in New York.

David A. Kempf has served as CFO, COO and Director of the Company since February 2009. From 2005 to January 2009 he served as CFO of InPhase Technologies, Inc., a venture backed holographic storage company. David has held CFO positions with Picolight, Inc., Loanbright, Inc., and International Verifact, Inc., In addition, he has held senior level positions with AMBIS, Ecrton Corp., AMETEK and Redken Labs. David has a broad range of experience gained from working at manufacturing based venture capital backed companies to Fortune 500 companies. He has raised over $100 million from venture, strategic and corporate investors at various stages of development from seed capital to public offerings. Mr. Kempf received his BS degree in Business Administration from United States International University in 1980.

---

Contact

BioMedical Technology Solutions, Inc.
9800 Mount Pyramid Court, Suite 250
Englewood, Colorado 80112

Phone:
Toll Free:
866.525.BMTS (2687)

In the Denver, Colorado Metro Area :
303.653.0100

Fax:
303.653.0120

Investor Relations:
David A. Kempf
CFO/COO
BioMedical Technology Solutions Holdings, Inc.
Phone: 303-653-0100

---

FORWARD LOOKING STATEMENTS

This report includes forward-looking statements that reflect BioMedical Technology Solutions Holdings, Inc. current expectations about its future results, performance, prospects and opportunities. BioMedical Technology Solutions Holdings, Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause BioMedical Technology Solutions Holdings, Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

---

Disclaimer

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for BioMedical Technology Solutions Holdings, Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2009 AllPennyStocks.com. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated fourteen thousand five hundred dollars by the Company for its efforts in presenting the BMTL profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.